Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

0.7734
+0.00120.16%
Post-market: 0.7723-0.0011-0.14%19:08 EDT
Volume:70.03K
Turnover:54.36K
Market Cap:15.21M
PE:-0.99
High:0.7904
Open:0.7900
Low:0.7601
Close:0.7722
52wk High:3.78
52wk Low:0.6900
Shares:19.67M
Float Shares:17.33M
Volume Ratio:0.52
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7779
EPS(LYR):-1.1986
ROE:-2543.13%
ROA:-39.29%
PB:-27.12
PE(LYR):-0.65

Loading ...

Dare Bioscience to present Sildenafil Cream data at SMSNA meeting

TIPRANKS
·
Oct 08

Daré Bioscience Reports Phase 1 Data Showing 187-Fold Lower Peak Plasma Sildenafil with 3.6% Topical Cream vs Oral Dose

Reuters
·
Oct 08

Dare Bioscience - Notified by NASDAQ of Non-Compliance with Minimum Bid Price Requirement - SEC Filing

THOMSON REUTERS
·
Oct 03

Daré Bioscience Gets NASDAQ Notice After Shares Trade Below $1 Minimum Bid Price

Reuters
·
Oct 03

Daré Bioscience Wins New US Patent Covering Topical Lopinavir-Ritonavir Formulation for DARE-HPV Program

Reuters
·
Sep 28

Dare Bioscience Announces New U.S. Patent Strengthening Dare-Hpv Program as a Potential First FDA-Approved Pharmacologic Treatment for Hpv Infection

THOMSON REUTERS
·
Sep 28

Daré Bioscience Reports Phase 1 Study Shows Topical Sildenafil Cream Cuts Systemic Exposure Versus Oral Dose

Reuters
·
Sep 14

Daré Bioscience Lowers Stockholder Meeting Quorum Requirement to One-Third Voting Power

Reuters
·
Sep 12

Daré Bioscience Posts H.C. Wainwright Investor Conference Presentation for On-Demand Viewing

Reuters
·
Sep 11

Daré Bioscience Wins NIH Award of About $908,000 for Preterm Birth Program DARE-PTB2

Reuters
·
Aug 31

Press Release: KB HOME NAMES CASEY DARE as President of ITS TAMPA Division

Dow Jones
·
Aug 28

Press Release: Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor "Why Now" On-Demand Series

Dow Jones
·
Aug 27

Dare Bioscience - Files for Resale of up to 8,934,345 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Aug 27

Daré Bioscience Posts Phase 1 Data Showing Topical Sildenafil Cream Well Tolerated in Postmenopausal Women

Reuters
·
Aug 26

Daré Bio CEO Flags Ovaprene Interim Phase 3 Results as Potential Catalyst in Investor Interview

Reuters
·
Aug 25

Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Dow Jones
·
Aug 25

Daré Bioscience DARE-HPV Program Advances with Non-Dilutive US Government Funding

Reuters
·
Aug 18

DarÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 over 50: Innovation” List

THOMSON REUTERS
·
Aug 18

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

GlobeNewswire
·
Aug 18

Daré Bioscience Prices USD 6 Million Registered Direct Offering at USD 1.37 Per Share

Reuters
·
Aug 17